title: ATP and P2X purinoceptors in urinary tract disorders.
abstract: The pharmacological concept of specifically targeting purinoceptors (receptors for ATP and related nucleotides) has emerged over the last two decades in the quest for novel, differentiated therapeutics. Investigations from many laboratories have established a prominent role for ATP in the functional regulation of most tissue and organ systems, including the urinary tract, under normal and pathophysiological conditions. In the particular case of the urinary tract, ATP signaling via P2X1 receptors participates in the efferent control of detrusor smooth muscle excitability, and this function may be heightened in disease and aging. Perhaps of greater interest, ATP also appears to be involved in bladder sensation, operating via activation of P2X3-containing receptors on sensory afferent neurones, both on peripheral terminals within the urinary tract tissues (e.g., ureters, bladder) and on central synapses in the dorsal horn of the spinal cord. Such findings are based on results from classical pharmacological and localization studies in nonhuman and human tissues, gene knockout mice, and studies using recently identified pharmacological antagonists - some of which have progressed as candidate drug molecules. Based on recent advances in this field, it is apparent that the development of selective antagonists for these receptors will occur that could lead to therapies offering better relief of storage, voiding, and sensory symptoms for patients, while minimizing the systemic side effects that curb the clinical effectiveness of current urologic medicines.
authors.affiliation: Afferent Pharmaceuticals, San Mateo, CA 94403, USA. AF@afferentpharma.com
authors.forename: Anthony P D W
authors.initials: AP
authors.lastname: Ford
authors.forename: Debra A
authors.initials: DA
authors.lastname: Cockayne
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D006801:Humans; D009434:Neural Pathways / Q000378:metabolism; D058920:Purinergic P2X Receptor Antagonists / Q000627:therapeutic use; D018048:Receptors, Purinergic P2 / Q000378:metabolism*; D058469:Receptors, Purinergic P2X / Q000187:drug effects / Q000378:metabolism*; D015398:Signal Transduction; D014551:Urinary Tract / Q000187:drug effects / Q000294:innervation / Q000378:metabolism* / Q000503:physiopathology; D014570:Urologic Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology
chemical_list: D058920:Purinergic P2X Receptor Antagonists; D018048:Receptors, Purinergic P2; D058469:Receptors, Purinergic P2X; D000255:Adenosine Triphosphate